Long Grove Pharmaceuticals

Executive Summary

Long Grove Pharmaceuticals is a US-based generic drug company that specializes in differentiated, ready-to-use sterile injectable and premix products for critical care. Founded in 2014 and headquartered in Buffalo Grove, Illinois, the company has carved a niche in addressing drug shortages through a proprietary supply chain and in-house R&D capabilities. Its core product portfolio includes premixed vasopressin, norepinephrine, and fluorescein injection, which are essential in hospital settings for managing hypotension and diagnostic procedures. By focusing on ready-to-use formulations, Long Grove enhances patient safety and operational efficiency for healthcare providers, reducing the risk of medication errors and preparation time. The company's strategy positions it as a reliable partner in the critical care generic drug market, where consistent supply and quality are paramount.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval of New Sterile Injectable60% success
• Q4 2026Expansion of Manufacturing Capacity70% success
• Q3 2026Strategic Distribution Partnership50% success